References in Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies - Mayo Clinic Proceedings
ORION-1 Inclisiran inhibits PCSK9 synthesis by RNA interference Planned interim analysis of a multi-center randomized controlled dose-finding trial Kausik. - ppt download
Inclisiran—New hope in the management of lipid disorders? - Journal of Clinical Lipidology
Estimation of the major cardiovascular events prevention with Inclisiran - ScienceDirect
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
Inclisiran Reduced LDL-C in Obese Patients | DAIC
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | NEJM
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
RNAi Inclisiran A Novel Approach to PCSK 9
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials | DAIC
RNAi Inclisiran A Novel Approach to PCSK 9
Inclisiran (siRNA) for the Treatment of Hypercholesterolemia: PDUFA Date Set as December 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
AHA 2019 – The Medicines Company reaches for the stars | Evaluate
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
Abstract 13503: Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials | Circulation
Inclisiran - Lappin - 2021 - Practical Diabetes - Wiley Online Library
Is Novartis' RNA Therapeutic Inclisiran Poised to Displace PCSK9 Antibodies and Become the Next Blockbuster Lipid-Lowering Drug?, Brent Osborne, Mike Rice
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis | Journal of the American College of Cardiology
ORION-4 — Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU)
